Atlas Trials

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Clinical trial NCT02914990 · COMPLETED

Trial details

NCT number
NCT02914990
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2016-12-29
Primary completion
2019-03-07
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.